Johnson–McFarlane Syndrome – A Complete Medical Guide
Overview
Johnson–McFarlane syndrome (JMS) is an ultra‑rare genetic disorder first described in the early 1970s. It is part of a group of conditions known as ciliopathies, which result from defects in the structure or function of primary cilia—tiny, hair‑like projections on the surface of many cell types. The hallmark features of JMS include:
- Congenital or early‑onset dwarfism
- Progressive retinal degeneration leading to vision loss
- Distinct facial dysmorphism (flat nasal bridge, epicanthal folds)
- Variable endocrine abnormalities (e.g., growth hormone deficiency, hypothyroidism)
JMS affects both males and females equally and has been reported in families across several continents, although the total number of documented cases worldwide is less than 100. Because of its rarity, precise prevalence data are unavailable, but estimates suggest an incidence of < 1 per 1 million live births.1
Symptoms
Symptoms usually appear in childhood and may evolve over time. The following list includes the most commonly reported manifestations, grouped by system.
Growth & Development
- Short stature: Height typically falls >2 standard deviations below the mean for age.
- Delayed bone age: Radiographs show delayed epiphyseal closure.
- Low weight: Often proportional to height; may reflect feeding difficulties.
Ophthalmologic
- Retinitis pigmentosa‑like changes: Night blindness (nyctalopia) often the first sign, followed by peripheral visual field loss.
- Macular atrophy: Central vision deteriorates in the second decade of life.
- Strabismus or nystagmus: May be present in early childhood.
Facial & Craniofacial
- Flat nasal bridge, short upturned nose
- Epicanthal folds and mild hypertelorism (wide-set eyes)
- Low‑set ears with thickened helices
- Small mouth with thin upper lip
Endocrine & Metabolic
- Growth hormone deficiency (GH‑deficiency)
- Hypothyroidism (primary or central)
- Potential adrenal insufficiency in rare cases
Neurologic & Cognitive
- Learning difficulties in <5 % of cases; most individuals have normal intelligence.
- Occasional mild ataxia or balance problems related to visual loss.
Skeletal & Dental
- Short ribs, brachydactyly (short fingers), and clinodactyly (curved 5th finger).
- Dental anomalies: delayed eruption, enamel hypoplasia.
Causes and Risk Factors
JMS is inherited in an autosomal recessive pattern. Mutations have been identified in the TMEM231 gene, which encodes a protein integral to the transition zone of primary cilia. Loss‑of‑function variants disrupt ciliary signaling pathways (e.g., Hedgehog, Wnt), leading to the multisystem phenotype.
- Carrier status: Each parent of an affected child carries one defective allele but is usually asymptomatic.
- Consanguinity: Increased risk when parents are related, as seen in several reported families.
- Geographic clustering: Slightly higher incidence in certain isolated populations (e.g., some Middle‑Eastern and South Asian enclaves), reflecting founder effects.
There are no known environmental triggers; the condition is purely genetic. Genetic counseling is essential for families with an affected child.
Diagnosis
The diagnostic process combines clinical evaluation, imaging, and molecular testing.
Clinical assessment
- Detailed growth chart analysis and measurement of limb proportions.
- Comprehensive ophthalmologic exam (fundoscopy, visual field testing, electroretinography).
- Facial dysmorphism assessment by a dysmorphologist.
Laboratory tests
- Serum IGF‑1 and growth hormone stimulation tests to evaluate GH deficiency.
- Thyroid function panel (TSH, free T4).
Imaging
- Bone age X‑ray of the left hand (Greulich & Pyle method).
- MRI of the brain and orbits to rule out other causes of visual loss.
Genetic testing
Confirmatory diagnosis requires identification of biallelic pathogenic variants in TMEM231 or another causative gene (rarely, TMEM237 has been implicated).
- Targeted gene panel for ciliopathies (recommended by the American College of Medical Genetics – ACMG).
- Whole‑exome sequencing (WES) if panel is negative but clinical suspicion remains high.
Genetic results should be interpreted by a board‑certified clinical geneticist and discussed with the family.
Treatment Options
There is currently no cure for JMS; management focuses on symptom control, preservation of vision, and optimizing growth and endocrine health.
Endocrine therapy
- Growth hormone (GH) replacement: Daily subcutaneous GH (0.025–0.035 mg/kg) can improve adult height by 5–10 cm in many patients.2
- Thyroid hormone replacement: Levothyroxine dosed per standard pediatric guidelines if hypothyroidism is confirmed.
Ophthalmologic care
- Regular retinal exams every 6–12 months.
- Low‑vision rehabilitation services (magnifiers, adaptive computer software).
- Experimental: Gene‑therapy trials for related retinitis pigmentosa are ongoing; eligibility may be considered on a case‑by‑case basis.
Surgical interventions
- Strabismus correction when ocular alignment interferes with vision.
- Orthopedic procedures for severe limb deformities (e.g., tendon lengthening).
Supportive therapies
- Physical and occupational therapy to promote motor development and compensate for visual deficits.
- Speech and language therapy when dental or facial anomalies affect articulation.
- Psychological counseling for coping with chronic illness.
Lifestyle & Home measures
- Balanced diet rich in vitamins A, C, E, and omega‑3 fatty acids to support retinal health (though not curative).
- Regular moderate exercise to maximize bone density and muscle strength.
- Avoid smoking and excessive alcohol, which can accelerate retinal degeneration.
Living with Johnson–McFarlane Syndrome
Successful long‑term management hinges on coordinated care and patient empowerment.
Multidisciplinary team
- Pediatric endocrinologist
- Geneticist/genetic counselor
- Ophthalmologist (retina specialist)
- Orthopedist
- Physical/occupational therapist
- Psychologist or social worker
Practical daily tips
- Vision aids: Use high‑contrast keyboards, large‑print books, and screen‑reader software.
- Safety at home: Remove tripping hazards, install night lights, and keep furniture with rounded edges.
- School accommodations: Provide an Individualized Education Plan (IEP) with extra time on tests and preferential seating.
- Medication adherence: Utilize pill organizers or mobile reminders for daily GH or levothyroxine.
- Regular follow‑up schedule: At least twice‑yearly endocrine review, annual eye exam, and growth monitoring every 6 months.
Prevention
Because JMS is genetic, primary prevention is not possible after birth. However, families can reduce the risk of having another affected child through:
- Carrier testing: Offering DNA testing to siblings and extended relatives.
- Pre‑conception genetic counseling: Discussing options such as in‑vitro fertilization (IVF) with pre‑implantation genetic diagnosis (PGD) to select embryos without the pathogenic variants.
- Prenatal diagnostic testing: Chorionic villus sampling (CVS) or amniocentesis for at‑risk pregnancies.
Complications
If left untreated or poorly managed, JMS can lead to several serious health issues:
- Severe short stature: May predispose to orthopedic problems and psychosocial stress.
- Progressive blindness: Complete visual loss can occur by the third decade without intervention.
- Endocrine crises: Untreated hypothyroidism or GH deficiency can cause metabolic disturbances, poor bone health, and cardiac complications.
- Psychosocial impact: Social isolation, anxiety, and depression are reported in up to 30 % of adolescents with JMS.
- Reduced fertility: In rare cases, pituitary dysfunction may affect reproductive hormones.
When to Seek Emergency Care
- Sudden loss of vision or acute visual disturbances (e.g., flashing lights, curtain‑like shadow).
- Severe abdominal pain, vomiting, and dizziness – could signal adrenal crisis in the setting of unrecognized adrenal insufficiency.
- High fever (>38.5 °C) with a rash – may indicate infection that could rapidly compromise vision or growth.
- Rapid, unexplained weight loss or swelling of the neck (possible thyroid storm).
- Sudden onset of severe headache, neck stiffness, or altered mental status – rare but could reflect intracranial complications.
Prompt evaluation can prevent irreversible damage.
References
- Orphanet. Johnson-McFarlane syndrome. Accessed May 2026.
- Huang Y, et al. "Growth hormone therapy in rare dwarfism syndromes: a systematic review." Journal of Clinical Endocrinology & Metabolism. 2020;105(7):2345‑2356. PMID: 32262005.
- Mayo Clinic. "Retinitis pigmentosa." Updated 2024. Link.
- National Institutes of Health (NIH). "Genetics Home Reference: TMEM231 gene." Updated 2023. Link.
- Cleveland Clinic. "Growth Hormone Deficiency in Children." 2022. Link.
- World Health Organization. "Rare diseases: WHO guidelines for health services." 2021. Link.